

The biotech industry is bouncing back as is evidenced by the iShares Biotech (IBB, \$). The industry was subject to product pricing concerns as evidenced by tweets from then presidential candidate Hillary Clinton. Many of these names were thrown out together. While many well-known names like Amgen (AMGN, \$) are trading well today, we continue to believe in a couple names including Valeant Pharmaceuticals (VRX, \$) and Editas Medicine (EDIT, \$) as companies with potential upside. As was well known, Valeant is bouncing back with a string of good news after the fears of debt repayment. Editas continues to be ahead in the patent fight for what we believe to be game-changing gene editing technology.